Abstract 3753
Background
The advanced practice nurse (APN), with ability to apply evidence in an integrated framework, assumes new roles and acts as benchmark for patient and other professionals. In the last two decades, nurses have developed new advanced roles. There is international experience of the implementation for new model, and organizational ways by integrating and integrate interventions for EPA. High positive results in coordinating services and multidisciplinary teams, facilitate continuity of care resulting better quality of life and greater satisfaction for patients.
Methods
Descriptive study with patients treated in the functional unit of the Catalan Institute of Oncology in year 2018. After literature review on roles for nurses in lung cancer, we review number of interventions and activity carried out by EPA.
Results
A total of 589 first cases lung cancer started their first treatment. Nurse visited 93.2% of them in the Lung Functional Unit (LFU). Type of treatment; surgical 26.41%, palliative chemotherapy 11.83%, concomitant chemo+ radiotherapy in 11.65%, immunotherapy 4.19%, TKis 3.1%, sequential chemo+radiotherapy 3.2%, neoadjuvant chemo 1.58%, chemo+immunotherapy 0.27%, neoadjuvant chemo+radiotherapy+surgery in 0.15% and the rest 37.62% with supportive or palliative treatment. A total of 2563 visits by nurse, 21.42% were first visits, 73.23% patients with active treatment and 4.7% that have completed the treatment but with some toxicity. A total of 3935 phone calls were attended by nurses, of which 81.19% were patients who made calls and 18.80% were nurses on phone for control. Derivation was resulting to emergency for 5.13% of patients. 87.79% cases presented in Lung tumors board needed coordination for visits and for complementary proves.
Conclusions
Incorporate the EPA in the multidisciplinary care helps to minimize complications, to improve coordination and avoid deviations of the care process. Key activities were: health education to patient and family on care and self-care, improve the compression of the disease, the treatment and the process, strengthen information, minimize problems and improve resources for the care process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract